Pfizer Inc. (NYSE:PFE) Shares Bought by Lakeside Advisors INC.

Lakeside Advisors INC. lifted its position in Pfizer Inc. (NYSE:PFE) by 46.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 9,512 shares of the biopharmaceutical company’s stock after acquiring an additional 3,000 shares during the period. Lakeside Advisors INC.’s holdings in Pfizer were worth $274,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $255,000. Brookstone Capital Management lifted its holdings in shares of Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after purchasing an additional 212,369 shares during the last quarter. ETF Store Inc. lifted its holdings in shares of Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 727 shares during the last quarter. Finally, Farmers Trust Co. lifted its holdings in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after purchasing an additional 4,410 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.8 %

Shares of NYSE:PFE traded down $0.22 on Wednesday, reaching $25.69. The company had a trading volume of 28,885,313 shares, compared to its average volume of 33,467,946. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $41.33. The stock has a 50-day moving average price of $27.23 and a 200 day moving average price of $28.79. The stock has a market capitalization of $145.47 billion, a P/E ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the firm earned $1.14 earnings per share. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PFE. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.